📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

Roivant Sciences Ltd (ROIV)

NASDAQ
Currency in USD
Disclaimer
11.255
+0.045(+0.40%)
Real-time Data
ROIV Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
11.19511.315
52 wk Range
8.24513.055
Prev. Close
11.21
Open
11.25
Day's Range
11.195-11.315
52 wk Range
8.245-13.055
Volume
1,336,187
Average Vol. (3m)
6,201,178
1-Year Change
3.8%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
ROIV Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
16.944
Upside
+50.546%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Roivant Sciences Ltd Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Employees
904

Compare ROIV to Peers and Sector

Metrics to compare
ROIV
Peers
Sector
Relationship
P/E Ratio
1.8x−6.4x−0.6x
PEG Ratio
0.00−0.150.00
Price / Book
1.5x2.9x2.6x
Price / LTM Sales
52.4x12.7x3.2x
Upside (Analyst Target)
51.7%111.8%46.5%
Fair Value Upside
Unlock7.3%6.6%Unlock

People Also Watch

369.56
ULTA
-0.12%
67.541
VKTX
+7.19%
45.09
SMCI
-5.55%
68.34
BMRN
-0.90%
41.31
DVN
-3.06%

FAQ

What Is the Roivant Sciences (ROIV) Stock Price Today?

The Roivant Sciences stock price today is 11.255

What Stock Exchange Does Roivant Sciences Trade On?

Roivant Sciences is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Roivant Sciences?

The stock symbol for Roivant Sciences is "ROIV."

What Is the Roivant Sciences Market Cap?

As of today, Roivant Sciences market cap is 8.29B.

What is Roivant Sciences Earnings Per Share?

The Roivant Sciences EPS is 6.09.

What Is the Next Roivant Sciences Earnings Date?

Roivant Sciences will release its next earnings report on Nov 11, 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.